Last month, the US Food & Drug Administration (FDA) took a bold step into the red-hot weight-loss market, announcing strict new limits on how companies can advertise compounded GLP-1 drugs. The primary target? Ads claiming these compounded drugs use the same active ingredients as blockbuster brands like Ozempic or Mounjaro. While the FDA frames this as a necessary move to protect consumers from confusion, a deeper legal question is emerging: does the government have the right to ban a statement that is scientifically and factually true?
The core of this argument is simple chemistry: Semaglutide is a specific molecule. Whether it is manufactured by a pharmaceutical giant or prepared in a compounding pharmacy, its chemical identity remains the same. When a company truthfully states that its product contains semaglutide, they are providing a verifiable fact.
The Supreme Court has historically been skeptical of the government’s efforts to keep the public in the dark “for their own good.” Precedent suggests that truthful commercial speech can only be restricted if the government has a substantial interest and uses the “least restrictive means” of achieving it. By prohibiting companies from mentioning their active ingredients, the FDA may be overstepping. After all, patients are less informed if they cannot learn if a lower-cost alternative shares an active ingredient with a brand-name drug.
Moreover, these ad restrictions create a “speaker-based” double standard. Under the new rules, a brand-name manufacturer can freely shout about their active ingredients while a compounding pharmacy is silenced on the exact same chemical fact. This kind of content discrimination usually triggers heightened scrutiny from the courts.
There are better ways to protect the public than a total gag order. If the FDA is worried about consumers confusing compounded drugs and FDA-approved ones, they could simply mandate clear disclosures.
Requiring a label that says, “This product is not FDA-approved and has not undergone the same clinical review as branded drugs,” would provide transparency without suppressing the truth.
The FDA’s concerns about manufacturing standards and dose consistency are legitimate public health issues. However, suppressing truthful speech is a blunt instrument for a delicate problem.
The truth is that legacy businesses like big pharma are notorious for encouraging the FDA to erect barriers to impede upstart competitors. Eventually, the courts may have to decide whether the government can suppress the truth in the name of consumer protection, where the real motive seems to be Big Pharma’s wish for competition prevention.
Image via Wikimedia Commons.
.jpg){kind=link}